Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1284
Peer-review started: November 3, 2020
First decision: November 20, 2020
Revised: December 2, 2020
Accepted: December 16, 2020
Article in press: December 16, 2020
Published online: February 26, 2021
Acute kidney injury is a serious disease.
To explore new methods for the treatment of acute kidney injury.
To examine the effect of alprostadil on continuous venous-venous hemofiltration (CVVH) in patients with acute renal injury (AKI).
This was a retrospective study of 100 intensive care unit patients with AKI.
The clinical effect in the alprostadil group was better than that in the control group (P < 0.05); The urine output of patients in the alprostadil group returned to normal (9.1 ± 2.0 d) quicker than in the control group (10.6 ± 2.5 d), the difference was statistically significant (P < 0.05); adverse reactions occurred in the alprostadil group compared with the control group, but the difference was not statistically significant (P > 0.05).
Alprostadil combined with CVVH in the treatment of severely ill patients complicated with AKI can effectively improve renal resistance index, partial pressure of oxygen in urine, and has a positive effect on improving renal function.
New treatment methods are required for patients with acute kidney injury.